PDF(Sci-hub)
Abstract：
Boron neutron capture therapy (BNCT) is a binary therapeutic modality based on the nuclear capture and fission reactions that occur when the stable isotope boron-10 is irradiated with neutrons to produce high-energy alpha particles and recoiling lithium-7 nuclei. In this Commentary we will focus on a number of papers that were presented at a Symposium entitled \"Current Clinical Status of Boron Neutron Capture Therapy and Paths to the Future\", which was held in September 2017 at the China National Convention Center in Beijing. Results were presented by clinicians from Japan, Finland, the United States, the China mainland and Taiwan, China who have been working in the multiple disciplines that are required for carrying out clinical BNCT. The main focus was on the treatment of patients with malignant brain tumors, recurrent tumors of the head and neck region, and cutaneous melanomas. The results obtained in treating these patients were reported in detail and, although most of the patients with brain tumors and head and neck cancer were not cured, there was evidence of some clinical efficacy. Although there are a number of problems that must be addressed, further clinical studies to evaluate the efficacy of BNCT are warranted. First, despite considerable effort by numerous investigators over the past 40 years, there still are only two boron-containing drugs in clinical use, L-boronophenylalanine (BPA) and sodium borocaptate (BSH). Therefore, until new and more effective boron delivery agents are developed, efforts should be directed to improving the dosing and delivery of BPA and BSH. Second, due to a variety of reasons, nuclear reactor-based BNCT has ended except for its use in the China mainland and Taiwan. Therefore, the future of BNCT depends upon the results of the ongoing Phase II clinical trials that are being carried out in Japan and the soon to be initiated trials that will be carried out in Finland. If the results obtained from these clinical trials are sufficiently promising, then BNCT will have a clear path to the future, especially for patients with the therapeutically challenging malignancies that in the past have been treated with reactor-based BNCT.
摘要：
硼中子俘获疗法（BNCT）是一种基于核俘获和裂变反应的二元治疗方式，该反应发生在稳定同位素硼10被中子辐照以产生高能α粒子并反冲锂7核时。在本评论中，我们将重点介绍在题为“硼中子俘获疗法的临床现状和未来之路”的研讨会上发表的许多论文。2017年9月在北京中国国家会议中心举行。结果由日本的临床医生介绍，芬兰,美国,中国大陆和台湾，中国一直在开展临床BNCT所需的多个学科工作。主要关注恶性脑肿瘤患者的治疗,头颈部复发性肿瘤，还有皮肤黑素瘤.详细报道了治疗这些患者的结果，尽管大多数患有脑肿瘤和头颈癌的患者没有治愈，有一些临床疗效的证据.尽管有许多问题必须解决，需要进一步的临床研究来评估BNCT的疗效.首先,尽管在过去的40年中，许多调查人员付出了巨大的努力，临床上仍然只有两种含硼药物，L-硼苯丙氨酸(BPA)和硼辛酸钠(BSH)。因此,直到开发新的更有效的硼释放剂，应努力改善BPA和BSH的给药和给药。第二,由于种种原因,除在中国大陆和台湾使用外，基于核反应堆的BNCT已经结束。因此,BNCT的未来取决于正在日本进行的II期临床试验的结果,以及即将在芬兰进行的临床试验的结果.如果从这些临床试验中获得的结果足够有希望，那么BNCT将有一条清晰的未来之路，特别是对于过去使用基于反应器的BNCT治疗的具有治疗挑战性的恶性肿瘤的患者。
